EF Hutton analyst Elemer Piros initiated coverage of Mind Medicine with a Buy rating and $21 price target. MindMed "reinvigorated clinical development of LSD," the "oldest psychedelic substance known to the Western world," said Piros. MindMed has initiated the first industry-sponsored randomized, controlled efficacy trial with LSD for any indication and the company has cash to support itself for more than two years, the analyst added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNMD:
